Respiratory Symptom Incidence among People Using Electronic Cigarettes, Combustible Tobacco, or Both

Reddy, Krishna P.; Schwamm, Eli; Kalkhoran, Sara; Noubary, Farzad; Walensky, Rochelle P.; Rigotti, Nancy A.

doi:10.1164/rccm.202012-4441le

Cited by 27 publications

(23 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that e-cigarettes, which contain smaller amounts of chemicals, do not reduce exposure to toxic chemicals when they are used with conventional cigarettes [ 38 ]. Reddy et al reported that dual use of e-cigarettes with combustible tobacco is significantly associated with incident respiratory symptoms compared with either product alone [ 39 ]. Dual use of e-cigarettes with conventional cigarettes were also related to greater nicotine dependence [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Use of heated tobacco products by people with chronic diseases: The 2019 JASTIS study

Nakama

Tabuchi

2021

PLoS ONE

View full text Add to dashboard Cite

Heated tobacco products (HTPs) have become popular recently. People with chronic disease, such as diabetes, cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD) and cancer, should quit smoking for treatment and recurrence of tobacco-related diseases. However, they have difficulty in quitting smoking, and they may start HTPs use to quit smoking. The purpose of this study is to examine the use of HTPs in people with chronic disease. We used data from an internet study, the Japan Society and New Tobacco Internet Survey (JASTIS). We analyzed 9,008 respondents aged 15–73 years in 2019 using logistic regression. Current use of tobacco products was defined as use within the previous 30 days. Prevalence of current HTP use including dual use and dual use with cigarettes was 9.0% and 6.1% respectively in total. By disease: hypertension 10.2% and 7.4%, diabetes 15.9% and 12.3%, CVD 19.2% and 15.7%, COPD 40.5% and 33.3%, and cancer 17.5% and 11.9%. Diabetes, CVD, COPD, and cancer were positively associated with current use of HTPs (odds ratios (ORs) and 95% confidence intervals (CIs): 1.48 (1.06, 2.07), 2.29 (1.38, 3.80), 3.97(1.73, 9.11), and 3.58(1.99, 6.44), respectively) and dual use of cigarettes and HTPs (ORs and 95% CIs: 2.23 (1.61, 3.09), 3.58 (2.29, 5.60), 7.46 (3.76, 14.80), and 2.57 (1.46, 4.55), respectively) after adjusting for confounders. People with chronic disease were more likely to use HTPs and HTPs together with cigarettes. Further research on the smoking situation of HTPs in patients with chronic diseases is necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of heated tobacco products by people with chronic diseases: The 2019 JASTIS study

Nakama

Tabuchi

2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Data from the largest RCT [18] indicate that 80% of the e-cigarette intervention group participants who successfully quit cigarette smoking are still using e-cigarettes. Further, recent research findings demonstrate that compared to e-cigarette only or cigarette-only use, dual use substantially increases the odds of developing respiratory symptoms [45] and cardiovascular risk factors [46].…”

Section: Policy Implicationsmentioning

confidence: 99%

E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo determine the effects of electronic cigarettes (e-cigarettes) as a therapeutic intervention compared to nicotine replacement therapy (NRT) on nicotine abstinence.MethodsTwo authors independently searched the PubMed, Embase, PsycInfo and Cochrane Central Register of Controlled Trials databases for articles published up to and including 10 July 2021. We included randomised controlled trials (RCTs) in which nicotine e-cigarettes were compared to NRT among current cigarette users. The primary outcome was abstaining from all nicotine-delivery devices. Secondary outcomes were 1) allocated product use (e-cigarettes or NRT) among successful cigarette quitters and 2) quitting cigarettes at the end of the trial using fixed-effect Mantel–Haenszel models.ResultsWe included four RCTs representing 1598 adult participants (51.0% females). The mean age of participants in these studies ranged from 41 to 54 years, while average baseline smoking ranged from 14 to 21 cigarettes per day. Compared to NRT, e-cigarette use was associated with lower nicotine abstinence rates at the longest follow-up (risk ratio 0.50 (95% CI 0.32–0.77)). Among successful cigarette quitters, the risk of allocated product use by the end of the observational time was higher for e-cigarette users compared to NRT (risk ratio 8.94 (95% CI 3.98–20.07)). E-cigarette users had higher cigarette smoking cessation rates compared to NRT users (risk ratio 1.58 (95% CI 1.20–2.08)).ConclusionsThe use of e-cigarettes as a therapeutic intervention for smoking cessation may lead to permanent nicotine dependence.

show abstract

“…Die Mehrzahl der E-Zigarettenraucher:innen konsumiert gleichzeitig Tabakzigaretten [33][34][35][36]. Bei dual-use ist im Vergleich zu ausschließlichem Tabakkonsum die Rate an Atembeschwerden, COPD, Herzbeschwerden und Herz-Kreislauferkrankungen erhöht [34][35][36][37]. Für die Praxis ist bedeutsam, dass nicht weniger Tabakkonsum, sondern nur der vollständige Rauchstopp das kardiovaskuläre Risiko reduziert [38].…”

Section: Gesundheitsrisiken Der E-zigaretteunclassified

Empfehlungen zum Umgang mit der elektronischen Zigarette (E-Zigarette)

2022

Pneumologie

View full text Add to dashboard Cite

Raucher:innen soll die E-Zigarette nicht zur Tabakentwöhnung empfohlen werden. Im Gegensatz zu Nikotinersatztherapie (NET) oder Medikamenten zur Unterstützung der Tabakentwöhnung werden E-Zigaretten von der Mehrheit der ausstiegswilligen Raucher:innen dauerhaft genutzt. Das anhaltende Inhalieren des E-Zigaretten-Aerosols beinhaltet Gesundheitsrisiken, deren Ausmaß bisher nicht abschätzbar ist. Raucher:innen, die auf E-Zigaretten umsteigen, haben ein erhöhtes Rückfallrisiko.Sollen lungenkranke Raucher:innen die E-Zigarette zur Tabakentwöhnung nutzen?Raucher:innen mit COPD, Asthma oder anderen Lungenkrankheiten sollen E-Zigaretten zur Tabakentwöhnung nicht empfohlen werden. Das Inhalieren entzündungsfördernder toxischer Substanzen und Aromen durch die E-Zigarette birgt das Risiko eines fortdauernden Schadens an den Bronchien und am Lungengewebe. Es gibt keine von der Industrie unabhängigen Forschungsergebnisse, die einen relevanten Vorteil der E-Zigarette gegenüber der Tabakentwöhnung nach medizinischen Leitlinien mit Beratung, Telefonberatung, Gruppenkursen und medikamentöser Unterstützung belegen.

show abstract

Respiratory Symptom Incidence among People Using Electronic Cigarettes, Combustible Tobacco, or Both

Cited by 27 publications

References 13 publications

Use of heated tobacco products by people with chronic diseases: The 2019 JASTIS study

Use of heated tobacco products by people with chronic diseases: The 2019 JASTIS study

E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials

Empfehlungen zum Umgang mit der elektronischen Zigarette (E-Zigarette)

Contact Info

Product

Resources

About